Brief: Thermogenesis Announces Immunecyte Joint Venture Acquires Key Technologies To Develop Fully Human Polyclonal And Monoclonal Antibody Therapeutics For COVID-19
April 13 (Reuters) - Thermogenesis Holdings Inc THMO.O :
* THERMOGENESIS ANNOUNCES ITS IMMUNECYTE JOINT VENTURE
ACQUIRES
KEY TECHNOLOGIES TO DEVELOP FULLY HUMAN POLYCLONAL AND
MONOCLONAL ANTIBODY THERAPEUTICS FOR COVID-19
Source text for Eikon: ID:nPn1vzQFNa
Further company coverage: THMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Thermogenesis Holdings
See all newsThermogenesis Holdings Inc expected to post earnings of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc reports results for the quarter ended in December - Earnings Summary
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Brief: Thermogenesis Holdings Says On Jan 8 Co Received Nasdaq Letter Notifying It No Longer Complies With Minimum Bid Price Requirement For Listing On Nasdaq